💸 The Tape

Curaleaf fired its latest shot Monday morning, a release titled “Curaleaf Challenges Aurora’s Unilateral Rejection of Its Enhanced Proposal.” The target was Aurora’s October 14 Notice of Change, in which the board unanimously told shareholders, for the second time, to reject the hostile bid. CEO Boris Jordan put it bluntly: “Shareholders deserve the facts, and the facts favor engagement, not obstruction.”

Here are the facts, including the ones neither side is leading with.

How we got here

Curaleaf says it sent private proposals in June and July; Aurora disputes that it refused to engage. In July, Aurora was selling shares through its at-the-market program at prices as low as $2.60. On August 18, Curaleaf went hostile with a cash-and-stock offer worth about $4 per share, roughly $272 million, against an unaffected Aurora price of $2.76. Aurora’s board rejected it on the strength of an inadequacy opinion from Fort Capital.

On October 5, Curaleaf raised the bid to an implied $5 per share, structured as $1 in cash plus 0.4013 Curaleaf shares, lifted the maximum potential consideration to $6, and extended the expiry to December 4. ATB Capital Markets called the revised bid “favorable for Aurora shareholders,” offering “more than the fair value.”

Then the plot thickened. On October 13, the newsletter Cultivated reported that Organigram had been in talks with Aurora in recent weeks about a possible acquisition. Neither company would comment. Organigram is 19.9 percent owned by British American Tobacco, which has put more than C$345 million into the company since 2021, much of it earmarked for international expansion. Curaleaf called the situation “outrageous,” complaining that it was being denied diligence access while “a much smaller Canadian company” appeared to be inside the tent.

On October 14, Aurora’s board rejected the enhanced bid. Executive Chairman and CEO Miguel Martin: “Curaleaf’s revised offer still does not reflect the value of the company Aurora shareholders own today.” Aurora is “debt-free with a strong cash position,” he said, and the bid asks shareholders to surrender that strength at a discount. The special committee’s advisor has contacted several parties and signed confidentiality and standstill agreements with “multiple groups.”

Curaleaf’s case

Monday’s release is a point-by-point rebuttal. The headline premiums: 86 percent to Aurora’s unaffected 30-day VWAP, 217 percent on an ex-cash basis, and 92 percent above the $2.60 Aurora itself accepted from ATM buyers in July. On multiples, Curaleaf says it is paying 14.3x Aurora’s 2026 adjusted EBITDA while its own shares trade at 13.7x, so Aurora shareholders are getting the richer valuation.

The sharper arguments are about process. Curaleaf says Fort Capital’s fees “may be contingent” on Aurora reaching an alternative transaction, that the firm disclosed no supporting analysis, and that Aurora has not sought a second, independent opinion. It points out that the special committee is shopping the company under the same market conditions it calls opportunistic when Curaleaf bids. And on synergies, Jordan’s position is simple: Aurora cannot demand proof of $40 million in cost savings while refusing the diligence that would let Curaleaf prove it. Seaport Research raised the same question on October 15, asking why Aurora gives other potential buyers access it denies the bidder with a live offer.

Aurora’s case, and the arithmetic that helps it

Aurora’s rejection rests on three claims: the price undervalues the company, Curaleaf’s stock is overvalued, and the deal is really about Aurora’s cash. The first is the standard target refrain. The second and third have numbers behind them.

Curaleaf’s own premium math implies Aurora carries roughly $1.60 per share in cash, which is why the ex-cash premium looks so much larger than the headline. Buying a debt-free company for stock and using its treasury is normal practice, as Curaleaf says, but it is also exactly what a target board is entitled to resist.

The stock point is stronger. The $5 figure was struck when Curaleaf traded near $10. Curaleaf peaked at $11.90 on September 23 and was around $8.40 on the OTCQX last week. At that price, $1 in cash plus 0.4013 shares is worth about $4.37, not $5. Aurora was trading at roughly $4.10, which means the market is pricing the bid almost exactly at its current paper value, with no expectation of a bump. Curaleaf argues in its own release that its trading price “can be reasonably regarded as a proxy” for underlying value. If that is true at $10, it is true at $8.40.

What Curaleaf actually wants

Observers keep pointing at the same asset: Aurora’s EU-GMP certified footprint and its medical distribution in Germany, Australia and beyond. Curaleaf’s pitch for the combined company is 17 countries, more than $1.5 billion in revenue, and at least $40 million in savings.

What happens next

Three paths. Aurora’s committee produces a competing transaction, with Organigram the name in circulation, and Curaleaf either tops it or walks. Curaleaf raises again before December 4, which would be the third price in four months and would signal how badly it wants the European assets. Or the bid expires with Aurora independent, cash intact, and a board that has twice said no to an 86 percent premium.

The tell to watch is not the press releases. It is Curaleaf’s share price, because the bid is denominated in it. Every dollar Curaleaf’s stock falls takes forty cents off what Aurora shareholders are being offered, and Aurora’s board knows it.

📺 Trade To Black

Earnings Preview and What's Next In Cannabis Rescheduling | TTB Presented by Flowhub

• Glass House sets the tone for earnings season (NYSE: GLAS): preliminary Q3 revenue of $56.8 million, record biomass of about 317,000 pounds, cost of production down to roughly $110 per pound and $39.7 million in cash, against an average selling price that slid to $150 per pound. The ATM is off and a director has resigned.

• Curaleaf vs. Aurora escalates: Curaleaf (TSX: CURA) fires back at Aurora’s (NASDAQ: ACB) second board rejection, arguing Aurora is opening the data room to other parties while locking out the only bidder with a live offer.

• Canada as a value hunting ground: Ewing Morris offers to buy up to 2.6 million shares of Decibel Cannabis (TSXV: DB) at $1.91, open until November 6, and the hosts weigh one analyst’s case that the sector’s cheapest paper is north of the border.

• Insiders Edge with Michael Bronstein of ATACH previews the DEA rescheduling week ahead: Judge Julius has kept the stay in place and given the DEA until Wednesday, October 21 to answer opponents’ motion to reopen the hearing for limited discovery and testimony, with no ruling yet on admitting the GAO report or on reopening.